Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis

Lee, Hyojeong and Jeong, Gwang Hun and Li, Han and Kim, Min Seo and Kim, Jae Seok and Park, Se Jin and Han, Young Joo and Lee, Keum Hwa and Kronbichler, Andreas and Hong, Sung Hwi and Ghayda, Ramy A. and Luchini, Claudio and Nottegar, Alessia and Koyanagi, Ai and Smith, Lee and Jacob, Louis and Dragioti, Elena and Radua, Joaquim and Cargnin, Sarah and Terrazzino, Salvatore and Thompson, Trevor and Yon, Dong Keon and Lee, Seung Won and Yang, Jee Myung and Wasuwanich, Paul and Shin, Jae Il and Gamerith, Gabriele (2021) Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis. European Review for Medical and Pharmacological Sciences, 25 (20). pp. 6232-6244. ISSN 2284-0729

[img]
Preview
Text
Published Version
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview
[img] Text
Accepted Version
Restricted to Repository staff only
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (586kB) | Request a copy
Official URL: http://dx.doi.org/10.26355/eurrev_202110_26993

Abstract

OBJECTIVE: It is controversial whether there is efficacy or safety benefit of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell lung cancer (NSCLC) compared to standard chemotherapy. We aim to assess the efficacy and safety of EGFR-TKIs compared to other chemotherapeutics in EGFR-mutated NSCLC. MATERIALS AND METHODS: Up to April 27th, 2020, PubMed, Embase, Medline, Scopus, Cochrane library, and ClinicalTrials.gov were searched for articles or trials meeting the inclusion criteria. After filtering, 230 eligible studies were initially identified. Data extraction followed PRISMA and included outcomes were progression-free survival (PFS), overall survival (OS), and severe adverse events (SAEs). Direct and indirect meta-analyses were generated in the context of log-linear mixed-effects models, with fixed effects for each relative comparison and random effects for each study. RESULTS: The results showed that EGFR-TKI therapy had improved PFS with a hazard ratio (HR) of 0.40 (95% CI: 0.36-0.44, p<0.001) compared to standard chemotherapy. Nevertheless, the EGFR-TKIs showed no benefit on OS (HR: 0.96, 95% CI: 0.83-1.10, p=0.556). In the analysis of adverse events, EGFR-TKIs had fewer SAEs than standard chemotherapy (HR: 0.29, 95% CI: 0.26-0.33, p<0.001). CONCLUSIONS: Our systemic review indicates that EGFR-TKI therapy has improved PFS, and reduced SAEs compared to standard chemotherapy in advanced EGFR-mutated NSCLC.

Item Type: Journal Article
Keywords: Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor, Tyrosine Kinase, Meta-Analysis
Faculty: Faculty of Science & Engineering
SWORD Depositor: Symplectic User
Depositing User: Symplectic User
Date Deposited: 06 Apr 2021 14:43
Last Modified: 02 Nov 2021 09:27
URI: https://arro.anglia.ac.uk/id/eprint/706477

Actions (login required)

Edit Item Edit Item